M923 (adalimumab biosimilar) / J&J  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
M923 (adalimumab biosimilar) / J&J
NCT02675023: Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects

Completed
1
603
Europe, US
M923, Adalimumab
Momenta Pharmaceuticals, Inc.
Healthy
07/16
07/16

Download Options